Published online before print October 14, 2008, doi: 10.1161/CIRCHEARTFAILURE.108.790774
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Articles |
Detection of Endogenous B-Type Natriuretic Peptide at Very Low Concentrations in Patients With Heart Failure
From the Scios Inc (J.O., U.S.), Mountain View, Calif; Intrinsic Bioprobes Inc (E.E.N., U.A.K., R.W.N.), Tempe, Ariz; Christ Hospital (S.M., S.S.), Cincinnati, Ohio; and Medivation Inc (A.A.P.), San Francisco, Calif.
Correspondence to Ute Schellenberger, PhD, Pioneer HiBred International, Inc, 700 A Bay Road. Redwood City, CA 94063. E-mail uschellenberger{at}gmail.com
Received May 6, 2008; accepted September 23, 2008.
Background— The myocardium secretes B-type natriuretic peptide (BNP) in response to stimuli associated with heart failure (HF). However, high immunoreactive-BNP levels in patients with HF are associated with a paradoxical lack of natriuretic response. We hypothesized that commercially available assays for immunoreactive BNP do not reflect the bioactivity of the natriuretic peptide system, because they measure both unprocessed inactive pro-BNP and mature BNP 1-32. We describe an assay for the detection of bioactive BNP 1-32 and confirm very low concentrations in plasma from HF patients.
Methods and Results— We developed a quantitative mass spectrometry immunoassay to capture endogenous BNP peptides using high affinity antibodies. Bound BNP and its truncated fragments were detected by matrix assisted laser desorption ionization–time of flight mass spectrometry based on their predicted masses. Mass spectrometry immunoassay revealed rapid in vitro degradation of BNP 1-32 in plasma, which requires plasma collection in the presence of high protease inhibitor concentrations. In 11 of 12 HF patients BNP 1-32 was detectable, ranging from 25 to 43 pg/mL. Several degraded forms of BNP were also detected at similarly low levels. In contrast, parallel measurements of immunoreactive BNP using the Biosite assay ranged from 900 to 5000 pg/mL.
Conclusions— Detection of endogenous BNP 1-32 requires special preservation of plasma samples. Mass spectrometry immunoassay technology demonstrates that HF patients have low levels of BNP 1-32. Commercially available immunoreactive-BNP assays overrepresent biological activity of the natriuretic peptide system because they cannot distinguish between active and inactive forms. This observation may, in part, explain the "natriuretic paradox."
Key Words: natriuretic peptides • diagnosis • circulation • heart failure • mass spectrometry
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., February 16, 2010; 55(7): 688 - 696. [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Borges, D. S. Rehder, J. W. Jarvis, M. R. Schaab, P. E. Oran, and R. W. Nelson Full-Length Characterization of Proteins in Human Populations Clin. Chem., February 1, 2010; 56(2): 202 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Lopez, T. Rezai, D. A. Sarracino, A. Prakash, B. Krastins, M. Athanas, R. J. Singh, D. R. Barnidge, P. Oran, C. Borges, et al. Selected Reaction Monitoring-Mass Spectrometric Immunoassay Responsive to Parathyroid Hormone and Related Variants Clin. Chem., February 1, 2010; 56(2): 281 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Boerrigter, L. C. Costello-Boerrigter, G. J. Harty, B. K. Huntley, A. Cataliotti, H. Lapp, and J. C. Burnett Jr. B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2009; 296(6): R1744 - R1750. [Abstract] [Full Text] [PDF]
|
|